Review of Pharmacology - 9E (2015)

Review of Pharmacology
New Drugs
specifically indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy. It is administered as subcutaneous injection.
45. Siltuximab: It is an anti-interleukin-6 (IL-6) chimeric monoclonal antibody that binds to human IL-6.1 IL-6 is a
multifunctional cytokine produced by various cells such as T cells, B cells, monocytes, fibroblasts and endothelial
cells. It is specifically indicated for the treatment of patients with multicentric Castleman’s disease who are human
immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.Dysregulated overproduction of
IL-6 from activated B cells in affected lymph nodes has been implicated in the pathogenesis of Castleman’s disease.
46. Suvorexant: It is an orexin receptor antagonist. The orexin neuropeptide signaling system is a central promoter
of wakefulness. Blocking the orexin receptor suppresses wakefulness. It is specifically indicated for the treatment of
insomnia (by oral route) characterized by difficulties with sleep onset and/or sleep maintenance.
47. Tavaborole: It is an oxaborole antifungal. It is specifically indicated for the topical treatment of onychomycosis of the
toenails due to Trichophyton rubrum orTrichophyton mentagrophytes.
48. Tedizolid: It is an antibacterial agent of the oxazolidinone class similar to linezolid. It is specifically indicated for the
treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates
of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and
methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group
(including Streptococcus inosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. It can be
given orally or intravenously.
49. Testosterone undecanoate: It is an ester of the testosterone that is specifically indicated for testosterone replacement
therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: primary
hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). It is administered
by intramuscular route. Recently intranasal gel of testosterone has also been approved for same indications.
50. Topiramate: The extended release formulation of topiramate has been approved as initial monotherapy in patients 10
years of age and older with partial onset or primary generalized tonic-clonic seizures and adjunctive therapy in patients
2 years of age and older with partial onset or primary generalized tonic-clonic seizures and as adjunctive therapy in
patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.
51. Umeclidinium: It is a long-acting muscarinic antagonist (LAMA). It is specifically indicated for the long-term, oncedaily,
maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and/or emphysema via inhalational route.
52. Vedolizumab: It is a humanized monoclonal antibody.Vedolizumab targets a protein called alpha-4-beta-7, an integrin
on inflammatory cells that causes these cells to adhere to the gastrointestinal tract. It is specifically indicated for adults
with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD) who have had an inadequate response
with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an
inadequate response with, were intolerant to, or demonstrated dependence on corticosteroid. It is indicated to induce
and maintain clinical response/clinical remission, achieve corticosteroid-free remission and improve the endoscopic
appearance of the mucosa (UC). It is administered intravenously.
53. Vorapaxar: It is a protease-activated receptor-1 (PAR-1) antagonist. It is specifically indicated for the reduction of
thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial
disease (PAD). It is administered by oral route.
736
https://kat.cr/user/Blink99/